Developing a cell line standard for HER2/neu

Cancer Biomarkers

Volumn 1, Issue 4-5, 2005, Pages 229-232

  Rhodes, Anthony ^a  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

cell lines; HER2 neu; immunohistochemistry; Predictive assays; standard reference materials

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BIOMEDICAL ENGINEERING; BREAST TUMOR; CYTOLOGY; GENE EXPRESSION PROFILING; HUMAN; METABOLISM; METHODOLOGY; REVIEW; STANDARD; TUMOR CELL LINE;

BIOMEDICAL ENGINEERING; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; RECEPTOR, ERBB-2; REFERENCE STANDARDS;

EID: 39049183566     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2005-14-505     Document Type: Article

References (27)

1. D.C. Allred and P.E.Swanson, Testing for erbB-2 by immunohistochemistry in breast cancer, Am J Clin Pathol 113 (2000), 171-175.
2. G.M. Clark, Prognostic and predictive factors, in: Diseases of the Breast Philadelphia, J.R. Harris, M.E. Lippman, M. Morrow and S. Hellman, eds, PA: Lippincott-Raven, 1996, pp. 461-485.
3. M.A. Cobleigh, C.L. Vogel, D. Tripathy et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol 17 (1999), 2639-2648.
4. M. Dowsett, I.O. Ellis, J.M.S. Bartlett et al., Correlation between immunohistochemistry and FISH for HER-2 in 441 breast carcinomas from multiple hospitals, J Pathol 195(supplement) (2001), 5A.
5. I.O. Ellis, J. Bartlett, M. Dowsett et al., Updated recommendations for HER2 testing in the UK, J Clin Pathol 57 (2004), 233-237.
6. M.E.H. Hammond, P. Barker, S. Taube and S. Gutman, Report of a National Institute of Standards and Technology sponsored Consensus Workshop, Applied Immunohistochemistry & Molecular Morphology 11 (2003), 103-106.
7. C.A. Moskaluk, Standardisation of clinical immunohistochemistry: Why, how and by whom? Am J Clin Pathol 118 (2002), 669.
8. M.D. Pegram, A. Lipton, D.F. Hayes et al., Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplastin in patients with HER2/neu-overexpressing metastatic breast cancer refactory to chemotherapy treatment, J Clin Oncol 16 (1998), 2659-2671.
9. M.F. Press, G. Hung,W. Godolphin et al., Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression, Cancer Res 54 (1994), 2771-2777.
10. A. Rhodes, D. Borthwick, R. Sykes et al., The use of cell line standards to standardise assays for HER2/neu in European cancer centres and the potential of automated image analysis to provide more accurate cut-points for predicting clinical response to trastuzumab, Am J Clin Pathol 122 (2004), 51-60.
11. A. Rhodes, B. Jasani, E. Anderson et al., Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin fixed and paraffin processed cell lines and breast carcinomas: A comparative study involving results from laboratories in 21 countries, Am J Clin Pathol 118 (2002), 408-417.
12. A. Rhodes, B. Jasani, A.J. Balaton et al., Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on 'in house' tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries, J Clin Pathol 53 (2000), 292-301.
13. A. Rhodes, B. Jasani, A.J. Balaton et al., Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7,016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value and mammographic screening, J Clin Pathol 53 (2000), 688-696.
14. A. Rhodes, B. Jasani, A.J. Balaton et al., Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays, Am J Clin Pathol 115 (2001), 44-58.
15. A. Rhodes, B. Jasani, D.M. Barnes et al., Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: inter-laboratory variance in the sensitivity of detection and evaluation of scoring systems, J Clin Pathol 53 (2000), 125-130.
16. A. Rhodes, B. Jasani, J. Couturier et al., A formalin fixed and paraffin processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer, Am J Clin Pathol 117 (2002), 81-89.
17. J. Riera, J.F. Simpson, R. Tamayo and H. Battifora, Use of cultured cells as a control for quantitative immunocytochemical anlalysis of estrogen receptor in breast cancer. The quicgel method, Am J Clin Pathol 111 (1999), 329-335.
18. P.C. Roche and J.N. Ingle, Increased HER-2 with US Food and Drug Administration approved antibody, J Clin Oncol 17 (1999), 434-435.
19. J.S. Ross, K. Gray, G.S. Gray et al., Anticancer antibodies, Am J Clin Pathol 119 (2003), 472-485.
20. S.G. Ruby and A.C. McNally, Quality control of imprint and tissue section DNA ploidy analysis in image analysis systems utilizing cell culture-based control materials, Am J Clin Pathol 104(2) (1995), 167-171.
21. S.G. Ruby and A.C. McNally, Quality control of prolilferation marker (MIB1) in image analysis systems utilizing cell culture-based control materials, Am J Clin Pathol 106(5) (1996), 634-639.
22. D.J. Slamon, G.M. Clark, S.G. Wong et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987), 177-182.
23. D. Slamon, B. Leyland-Jones, S. Shak et al., Addition of Herceptin (humanized anti-Her2 anitbody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (Her2+/MBC) markedly increases anticancer activity: a randomised multinational controlled phase III trial, Proc ASCO 17 (1998), 98A. Abstract 377.
24. P.E. Swanson, Labels, disclaimers and Rules (Oh, My!): Analyte-specific reagents and practice of immunohistochemistry, Am J Clin Pathol 111 (1999), 445-448.
25. C.R. Taylor, FDA issues final rule for classification of reclassification of immunochemistry reagents and kits, Am J Clin Pathol 111 (1999), 443-444.
26. M.R. Wick and P.E. Swanson, Editorial: Targeted controls in clinical immunohistochemistry; a useful approach to quality assurance, Am J Clin Pathol 117 (2002), 7-8.
27. J.L. Wisecarver, Editorial: HER-2/neu testing comes of age, Am J Clin Pathol 111 (1999), 299-301.